QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.104.003244v1 33/5/676    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sandhu, P. Articles by Kim, R. B. Search for Related Content PubMed PubMed Citation Articles by Sandhu, P. Articles by Kim, R. B.

HEPATIC UPTAKE OF THE NOVEL ANTIFUNGAL AGENT CASPOFUNGIN

Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee (W.L., B.F.L., R.B.K.); and Department of Drug Metabolism, Merck Research Laboratories, West Point, Pennsylvania (P.S., X.X., M.Y., J.A.S., J.H.L., P.G.P.)

Caspofungin (CANCIDAS, a registered trademark of Merck & Co., Inc.) is a novel echinocandin antifungal agent used in the treatment of esophageal and invasive candidiases, invasive aspergillosis, and neutropenia. Available data suggest that the liver is a key organ responsible for caspofungin elimination in rodents and humans. Caspofungin is primarily eliminated by metabolic transformation; however, the rate of metabolism is slow. Accordingly, it was hypothesized that drug uptake transporters expressed on the basolateral domain of hepatocytes could significantly influence the extent of caspofungin uptake and subsequent elimination. In this study, experiments ranging from perfused rat livers to heterologous expression of individual hepatic uptake transporters were utilized to identify the transporter(s) responsible for the observed liver-specific uptake of this compound. Data from perfused rat liver studies were consistent with the presence of carrier-mediated caspofungin hepatic uptake, although this process appeared to be slow. To identify a relevant hepatic uptake transporter, we developed novel Tet-on HeLa cells expressing OATP1B1 (OATP-C, SLC21A6) and OATP1B3 (OATP8, SLC21A8), whose target gene can be overexpressed by the addition of doxycycline. A modest but statistically significant uptake of caspofungin was observed in cells overexpressing OATP1B1, but not OATP1B3. Taken together, these findings suggest that OATP1B1-mediated hepatic uptake may contribute to the overall elimination of this drug from the body.

This article has been cited by other articles:

				M. Miyagawa, K. Maeda, A. Aoyama, and Y. Sugiyama The Eighth and Ninth Transmembrane Domains in Organic Anion Transporting Polypeptide 1B1 Affect the Transport Kinetics of Estrone-3-Sulfate and Estradiol-17{beta}-D-glucuronide J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 551 - 557. [Abstract] [Full Text] [PDF]

				M. Neely, H. S. Jafri, N. Seibel, K. Knapp, P. C. Adamson, S. K. Bradshaw, K. M. Strohmaier, P. Sun, S. Bi, M. F. Dockendorf, et al. Pharmacokinetics and Safety of Caspofungin in Older Infants and Toddlers Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1450 - 1456. [Abstract] [Full Text] [PDF]

				X. Saez-Llorens, M. Macias, P. Maiya, J. Pineros, H. S. Jafri, A. Chatterjee, G. Ruiz, J. Raghavan, S. K. Bradshaw, N. A. Kartsonis, et al. Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of Age Antimicrob. Agents Chemother., March 1, 2009; 53(3): 869 - 875. [Abstract] [Full Text] [PDF]

				B. D. Damle, J. A. Dowell, R. L. Walsky, G. L. Weber, M. Stogniew, and P. B. Inskeep In Vitro and In Vivo Studies To Characterize the Clearance Mechanism and Potential Cytochrome P450 Interactions of Anidulafungin Antimicrob. Agents Chemother., March 1, 2009; 53(3): 1149 - 1156. [Abstract] [Full Text] [PDF]

				A. Kalliokoski, M. Neuvonen, P. J. Neuvonen, and M. Niemi Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide J. Clin. Pharmacol., March 1, 2008; 48(3): 311 - 321. [Abstract] [Full Text] [PDF]

				G. C. Mistry, E. Migoya, P. J. Deutsch, G. Winchell, M. Hesney, S. Li, S. Bi, S. Dilzer, K. C. Lasseter, and J. A. Stone Single- and Multiple-Dose Administration of Caspofungin in Patients With Hepatic Insufficiency: Implications for Safety and Dosing Recommendations J. Clin. Pharmacol., August 1, 2007; 47(8): 951 - 961. [Abstract] [Full Text] [PDF]

				J. A. Dowell, M. Stogniew, D. Krause, T. Henkel, and B. Damle Lack of Pharmacokinetic Interaction Between Anidulafungin and Tacrolimus J. Clin. Pharmacol., March 1, 2007; 47(3): 305 - 314. [Abstract] [Full Text] [PDF]

				J. L. Lam, S. B. Shugarts, H. Okochi, and L. Z. Benet Elucidating the Effect of Final-Day Dosing of Rifampin in Induction Studies on Hepatic Drug Disposition and Metabolism J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 864 - 870. [Abstract] [Full Text] [PDF]

				J. Meletiadis, S. Chanock, and T. J. Walsh Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy Clin. Microbiol. Rev., October 1, 2006; 19(4): 763 - 787. [Abstract] [Full Text] [PDF]